Moreover, MAPK pathway inhibition using erlotinib and selumetinib did not influence IFNγ‐induced upregulation of MHC‐I expression, suggesting that MHC‐I‐mediated tumor cell antigen presentation will not be impaired by these drugs. The gene discussed is IFNG; the disease is neoplasm.